BRAF and neoplasm: No distinction was found when differentiating tumor subtype (luminal or basal), immune score (score 1-5 from lowest non-T-cell inflamed to highest T-cell inflamed) (41), the presence of the BRAF mutation, or tumor grade (tumor grades 2-4 included in this study) (41) (Supplementary Figures 1, 2).